Exelixis, Inc. (NASDAQ:EXEL)

CAPS Rating: 5 out of 5

A development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases.

Recs

0
Player Avatar BruceInCola (98.91) Submitted: 10/24/2011 2:06:23 PM : Outperform Start Price: $5.63 EXEL Score: -25.44

9.75

Featured Broker Partners


Advertisement